South China Vaccine Corporation Limited (SCVC) is Currently located in guangzhou science city international business incubator . We are committed to the research and development of the core technologies of genetic engineering vaccine and the establishment of the R & D and manufacturing platform. Our focus: baculovirus-insect cell expression vector system (BEVS) based vaccines.
Our R & D team has accumulated rich experience in virology, immunology, cell biology, the large-scale culture of insect and mammalian cells and purification protein, peptide epitope design, the development of tumor vaccine and pharmacological study. We collaborate with “Vaccine and Infectious Disease Organization-International Vaccine Center” (VIDO-InterVac) in Canada, focusing on technology the vaccine R & D talents, vaccine adjuvant development, and vaccine efficacy evaluation, the cooperative development of vaccine projects.
Since SCVC has set up, as the undertaking unit, we have assumed many special projects, such as international cooperation vaccine projects between China and Canada, special projects of Science and Technology in Guangdong province and the collaborative innovation projects of health medical in Guangzhou city, etc. We acquired the inspection certificate of working virus banks for vaccine production from National Institutes for Food and Drug Control. Our company has applied twelve patents related to gene engineering vaccine technology, of which five have been awarded. We have also obtained the respective supports for several science and technology projects from the Guangzhou Development Zone.